<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473121</url>
  </required_header>
  <id_info>
    <org_study_id>15807</org_study_id>
    <secondary_id>NX1110TR</secondary_id>
    <nct_id>NCT01473121</nct_id>
  </id_info>
  <brief_title>Hepatocellular Carcinoma Registry for Turkey (3K Trial)</brief_title>
  <official_title>Profile of the Hepatocellular Carcinoma Patients in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry study is national, multi-center, prospective study without any interventions to
      the treatment strategies and/or decisions of the investigators. It is designed in order to
      determine the general profile of HCC patients in Turkey. Socio-demographic characteristics,
      family history, medical history and treatment pattern of HCC patients will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2012</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptive analysis of HCC risk factors</measure>
    <time_frame>Baseline</time_frame>
    <description>i.e. smoking and alcohol consumption status; family history for hepatitis, HCC, and other malignancies; history of hepatic disease and blood transfusion; concomitant diseases; treatments applied</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of clinical profile of newly diagnosed HCC patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with underlying liver disease and family history</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment options as applied by doctors to HCC patients</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time since diagnosis</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of demographic characteristics of HCC patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of clinical characteristics of HCC patients</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of tumor properties</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>All treatment options (inc. surgery, TACE, drugs) will be registered.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that are diagnosed with hepatocellular carcinoma in last 3 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be diagnosed with hepatocellular carcinoma in last 3 months

          -  To be older than 18 years old

          -  To sign informed consent form (ICF)

        Exclusion Criteria:

          -  Patients that does not sign or withdraw informed consent form.

          -  According to investigator's opinion; existence of any situation/condition that will
             significantly complicate patient follow up.

          -  Currently or previously taking part in 3K observational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Registry</keyword>
  <keyword>Turkey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

